Project description:Brown rice-specific bioactive substance, γ-oryzanol ameliorates fuel dysmetaborism, but it is hardly absorbed form the intestine. To increase the efficiency of its absorption, we therefore challenged to encapsulate γ-oryzanol in polymer poly (DL-lactide-co-glycolide) (PLGA) nanoparticles. We assessed the metabolically-beneficial impact of PLGA-encapusulated γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice.
Project description:Transcriptional profiling of gamma-oryzanol-treated (24h) differentiating equine satellite cells (3rd day of differentiation) compared to control GO-untreated cells. Goal was to determine the effects of gamma-oryzanol influence on gene expression in equine satellite cells during in vitro myogenesis
Project description:Transcriptional profiling of gamma-oryzanol-treated (24h) differentiating equine satellite cells (3rd day of differentiation) compared to control GO-untreated cells. Goal was to determine the effects of gamma-oryzanol influence on gene expression in equine satellite cells during in vitro myogenesis Two-condition experiment, GO-treated (24h) differentiating equine satellite cells (3rd day of differentiation) vs. differentiating equine satellite cells without GO treatment (control). Biological replicates: 4 reps of examined condition (Cy5), 4 control replicates (Cy3)
Project description:Transcriptomic analysis comprehensively revealed the metabolic improvement effects of di-SQ on the liver and white adipose tissue in ob/ob mice. Di-SQ demonstrated effects in improving inflammation and lipid metabolism in both the liver and white adipose tissue of ob/ob mice and restored the expression of genes and GO terms associated with mitochondrial respiration and glucose metabolism. The metabolic disorder observed in untreated ob/ob mice was reversed by a 42-day-di-SQ treatment, the di-SQ treated ob/ob mice showed a gene expression pattern in key metabolic pathways and processes that more closely resembles that of wild-type mice.
Project description:We have performed measured levels of metabolites involved in gluconeogenesis in liver. Over-night fasted ob ob mice that were injected with vehicle or FGF1 for 2h were used for the analysis.
Project description:An Infinium microarray platform (HorvathMammalMethylChip320) was used to generate DNA methylation data from n=48 liver samples from mice. Treatment: encapsulated rapamycin treated or control mice
Project description:BACKGOUND: Drinking water can be contaminated with pharmaceuticals. However, it is uncertain whether this contamination can have harmful consequences for the liver, especially in the context of obesity. OBJECTIVES: To determine whether chronic, low dose exposure to pharmaceuticals could have deleterious effects in livers of lean and obese mice. METHODS: Lean and ob/ob male mice (5-week-old) were treated for 4 months with a mixture of 11 drugs (acetaminophen, caffeine, carbamazepine, cotinine, diclofenac, erythromycin, ibuprofen, phenazone, roxithromycin, salicylic acid and sulfamethoxazole) provided in drinking water at a concentration of 1 mg/L (for each drug). At the end of the treatment, investigations were performed in liver and plasma. RESULTS: Some liver and plasma abnormalities were observed in ob/ob mice treated with the cocktail containing 1 mg/L of each drug. For this dosage, a gene expression analysis by microarray showed altered expression of circadian genes (e.g. Bmal1, Dbp, Cry1) in lean and obese mice. RT-qPCR analyses carried out in all groups of animals indicated that expression of 8 different circadian genes was significantly modified in a dose-dependent manner. For some genes, a significant modification was observed for dosages as low as 100-1,000 ng/L. Drug mixture and obesity presented an additive effect on circadian gene expression. These data were confirmed in an independent study performed in female mice. CONCLUSIONS: Chronic, low dose exposure to pharmaceuticals disturbed hepatic expression of circadian genes, especially in obese mice. Because some of the 11 drugs can be found in the drinking water at such concentrations (e.g. acetaminophen, carbamazepine, ibuprofen) our data could be relevant in environmental toxicology, in particular for obese individuals exposed to these contaminants. C57BL/6J lean and ob/ob male mice (5-week-old) were treated for 4 months with a mixture of 11 drugs provided in drinking water at a concentration of 1 mg/L (for each drug). 4 groups were designed: untreated versus treated WT and ob/ob mice (n=6 mice per group).
